|
Market Closed -
Other stock markets
|
Pre-market 07:14:25 | |||
| 0.5640 EUR | -7.84% |
|
0.5660 | +0.35% |
| 07-13 | AB Science to Discontinue Three Masitinib-related Clinical Studies | MT |
| 07-10 | AB Science streamlines its portfolio and refocuses on two molecules |  |
Main competitors
| Dividend Yield (Y) | Dividend Yield (Y+1) | P/E (Y) | Price to Book (Y) | EV / Sales (Y) | EV / EBITDA (Y) | EV / EBIT (Y) | Capi.($) | ||
|---|---|---|---|---|---|---|---|---|---|
 | - | - | - | - | - | - | - | 51.49M | |
| 2.73% | 2.8% | 63.33x | 5.94x | 5.13x | 19.07x | 25.52x | 307B | |
| 1.73% | 1.8% | 22.9x | 1.91x | 3.15x | 11.24x | 18.55x | 66.94B | |
| 2.59% | 2.77% | 17.18x | 1.49x | 2.19x | 7.5x | 8.97x | 8.55B | |
| -.--% | -.--% | 20.49x | 5.45x | 5.78x | 16.35x | 17.09x | 4.07B | |
| 0.8% | 0.81% | 38.42x | 2.29x | 2.17x | 26.77x | 40.41x | 3.49B | |
| -.--% | -.--% | 106.56x | - | - | - | - | 2.75B | |
| 4.08% | 3.52% | 17.33x | 0.76x | 1.36x | 24.3x | 41.6x | 1.06B | |
| Average | 1.71% | 1.67% | 40.89x | 2.97x | 3.30x | 17.54x | 25.36x | 49.27B | |
| Weighted average by Cap. | 2.5% | 2.56% | 54.98x | 5.10x | 4.70x | 17.53x | 24.06x |
- Stock Market
- Stocks
- AB Stock
- Sector AB Science
- Sector dividends
Select your edition
All financial news and data tailored to specific country editions
